Together-Breast Cancer Support Platform (Together)

March 24, 2026 updated by: Jin Sun Bitar, Cedars-Sinai Medical Center

"Together": A Bilingual Online Platform Support Intervention Project for Korean Breast Cancer Survivors

The goal of this study is to evaluate the acceptability and engagement of a culturally tailored online peer-support program for Korean speaking breast cancer patients and survivors. The main questions it aims to answer are: 1) Is the peer-support program acceptable and sustainable in terms of engagement between mentors and mentees over a 12-week period? 2) Does participation in the program improve quality of life, psychological well-being (including anxiety and depression), and perceived social support?

Participants will include Korean speaking breast cancer survivors (mentors) and patients currently undergoing treatment (mentees). After enrollment and matching based on screening information, participants will engage in peer-support interactions through an online platform for 12 weeks. Surveys will be administered at baseline, mid-point, post-intervention, and optional 6-month follow-up to assess outcomes.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

This study evaluates the acceptability and engagement of a culturally tailored online peer-support program for Korean speaking breast cancer patients and survivors, as well as its potential impact on psychosocial outcomes.

A total of 24 participants will be enrolled, including 8 mentors (breast cancer survivors diagnosed at least two years prior who have completed active treatment or are on long-term maintenance therapy) and 16 mentees (patients currently undergoing treatment).

Participants will be recruited through community outreach using study flyers with a QR code that links to an online eligibility screener. Individuals who complete the screener will be contacted by the study coordinator to confirm eligibility and complete the informed consent process prior to enrollment.

Mentors and mentees will be matched based on information collected from the screener, including demographic and clinical characteristics such as age group and cancer stage at diagnosis. Each mentor may be matched with up to two mentees.

Mentors will complete a structured training program prior to participation. All participants will engage in peer-support interactions through an online platform over a 12-week period, with a minimum expectation of at least one bidirectional interaction per week.

Data will be collected using REDCap. Participants will complete surveys at baseline, mid-intervention (weeks 4-5), and post-intervention (weeks 12-13), with an optional follow-up survey at 6 months.

Outcome measures include engagement metrics, quality of life, psychological well-being (including anxiety and depression), and perceived social support.

Study Type

Observational

Enrollment (Estimated)

24

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90048

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of Korean American breast cancer patients and survivors. Participants include mentors (breast cancer survivors diagnosed at least two years prior and who have completed treatment or are on long-term maintenance therapy) and mentees (patients currently undergoing active breast cancer treatment). All participants are required to have access to a smartphone or computer and be able to participate in an online peer-support platform. Participants will be recruited through community outreach, referrals, and self-referral using a QR code-based screening process.

Description

Inclusion Criteria:

Mentors:

  • Age ≥ 18 years
  • Self-identify as Korean
  • Able to read, write, and speak both Korean and English
  • Diagnosed with breast cancer ≥ 2 years prior to enrollment
  • Completed active treatment or currently on long-term maintenance therapy
  • Access to a smartphone, computer, or similar device compatible with the study platform
  • Willing to participate for at least 3 months
  • Willing to complete required training and surveys

Mentees:

  • Age ≥ 18 years
  • Self-identify as Korean
  • Able to read, write, and speak Korean
  • Diagnosed with breast cancer
  • Currently receiving treatment (e.g., chemotherapy, radiation therapy, recent surgery, or endocrine therapy)
  • Access to a smartphone, computer, or similar device compatible with the study platform
  • Willing to participate for at least 3 months
  • Willing to complete required surveys

Exclusion Criteria:

  • Individuals who do not meet the inclusion criteria
  • Individuals unable to use the online platform or required technology
  • Individuals deemed non-compliant or inappropriate for participation based on investigator judgment (e.g., inability to complete study procedures)
  • Mentees diagnosed with ductal carcinoma in situ (DCIS)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Mentors
Korean breast cancer survivors who complete mentor training and provide peer support to matched mentees through the Together online platform.
Mentees
Korean breast cancer patients currently receiving treatment who are matched with trained mentors and participate in peer-support interactions through the Together online platform.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of peer-support platform engagement
Time Frame: Week 1 to Week 12
Feasibility is defined as the proportion of mentor-mentee pairs achieving at least one bidirectional interaction per week for at least 8 out of 12 weeks during the study period.
Week 1 to Week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in quality of life (FACT-B score)
Time Frame: Baseline to Week 12
Quality of life will be assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire, which includes physical, social/family, emotional, and functional well-being domains.
Baseline to Week 12
Change in social/family well-being (FACT-B social/family subscale)
Time Frame: Baseline to Week 12
Social/family well-being will be assessed using the social/family well-being subscale of the FACT-B questionnaire.
Baseline to Week 12
Change in self-efficacy score
Time Frame: Baseline to Week 12
Self-efficacy will be assessed using the self-efficacy scale included in the study questionnaire administered at baseline, mid-study, and post-study.
Baseline to Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cedars-Sinai Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

April 30, 2027

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

March 24, 2026

First Submitted That Met QC Criteria

March 24, 2026

First Posted (Actual)

March 30, 2026

Study Record Updates

Last Update Posted (Actual)

March 30, 2026

Last Update Submitted That Met QC Criteria

March 24, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Study00003360

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No, individual participant data will not be made available to other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe